ArticleClinicoEconomics and outcomes research : CEOR2018

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.

Cheryl P Ferrufino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.